Every Form 4 that Kiora Pharmaceuticals, Inc. (KPRX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow KPRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KPRX filings page.
Kiora Pharmaceuticals Inc. (KPRX) reported that executive Keith J. Lane, EVP, Clinical and Regulatory, received a grant of stock options for 55,000 shares of Common Stock on September 17, 2026. The options have an exercise price of $2.67 per share and expire on September 17, 2036.
According to the award terms, the option becomes exercisable as to one-third of the shares on September 17, 2027, with the remaining balance vesting monthly on the last day of each month over the following two years, subject to Mr. Lane’s continuous service. No Rule 10b5-1 trading plan is reported for this grant.
Kiora Pharmaceuticals CFO Melissa Tosca reported a small insider transaction involving company common stock. On July 1, 2026, 911 shares were disposed of at $2.66 per share as a tax-withholding disposition, meaning shares were delivered to satisfy tax obligations rather than sold on the open market. Following this transaction, Tosca directly holds 26,064 shares of Kiora Pharmaceuticals common stock.
Kiora Pharmaceuticals' President and CEO Brian M. Strem reported a small share disposition related to taxes. On July 1, 2026, he had 1,869 shares of Kiora common stock transferred at $2.66 per share as a tax-withholding disposition, meaning shares were delivered to cover tax obligations rather than sold on the open market. After this transaction, he directly owns 58,823 common shares, so the adjustment represents a minor change in his overall stake.
Kiora Pharmaceuticals director Carmine N. Stengone received a stock option grant as part of equity compensation. On June 10, 2026, he was awarded options covering 25,000 shares of common stock at an exercise price of $2.63 per share, with no cash paid for the grant itself.
The options were granted under Kiora’s 2024 Equity Incentive Plan and will become fully exercisable on June 10, 2027. They expire on June 10, 2036 if not exercised. After this award, Stengone holds options for 25,000 underlying shares directly, and the filing does not report any open‑market purchases or sales.
Kiora Pharmaceuticals director Aron Shapiro received a grant of stock options as part of equity compensation. The award covers 25,000 options for Common Stock at an exercise price of $2.63 per share, becomes fully exercisable on June 10, 2027, and expires on June 10, 2036.
Kiora Pharmaceuticals director Erin Parsons reported a compensation-related stock option grant. She received options to buy 25,000 shares of Kiora common stock at an exercise price of $2.63 per share under the company’s 2024 Equity Incentive Plan.
The options will become fully exercisable on June 10, 2027 and expire on June 10, 2036. After this grant, Parsons holds options covering 25,000 shares. This is an award, not an open-market purchase or sale of stock.
Kiora Pharmaceuticals director David Hollander received a grant of stock options as compensation. He was awarded options covering 25,000 shares of common stock at an exercise price of $2.63 per share, issued under the company’s 2024 Equity Incentive Plan.
The options will become fully exercisable on June 10, 2027 and are scheduled to expire on June 10, 2036 if not exercised. After this grant, Hollander holds 25,000 stock options directly, giving him potential future ownership if the options are exercised.
Kiora Pharmaceuticals director Lisa Walters-Hoffert received a grant of stock options as part of her compensation. She was awarded 25,000 options to buy Kiora common stock at an exercise price of $2.63 per share under the company’s 2024 Equity Incentive Plan.
The options were granted at no cost and relate to 25,000 underlying shares of common stock. They will become fully exercisable on June 10, 2027 and will expire on June 10, 2036 if not exercised. After this grant, she holds 25,000 options directly, and the filing reports no open-market purchases or sales.
Kiora Pharmaceuticals director Praveen Tyle received a grant of stock options as equity compensation. The award covers options on 40,000 shares of common stock at an exercise price of $2.63 per share under the 2024 Equity Incentive Plan.
The options become fully exercisable on June 10, 2027 and expire on June 10, 2036. Following this grant, Tyle holds options on 40,000 shares directly, with no open-market buying or selling reported in this filing.
Kiora Pharmaceuticals CFO Melissa Tosca reported a routine tax-related share disposition. On April 1, 2026, 929 shares of Kiora Pharmaceuticals common stock were delivered at $1.95 per share to pay an exercise price or tax liability. After this tax-withholding disposition, Tosca directly holds 26,975 shares of common stock, indicating the transaction affected only a small portion of her position and was not an open-market sale.
Kiora Pharmaceuticals Chief Development Officer Eric Joseph Daniels reported a tax-related share disposition. On the transaction date, 929 shares of Kiora Pharmaceuticals common stock were withheld at $1.95 per share to cover tax obligations. After this non-open-market tax-withholding disposition, Daniels directly held 31,741 shares of common stock.
Kiora Pharmaceuticals President and CEO Brian M. Strem reported a tax-related share disposition. On April 1, 2026, he transferred 1,906 shares of Common Stock at $1.95 per share to cover taxes by delivering shares instead of cash. After this tax-withholding disposition, he directly holds 60,692 shares of Kiora common stock. This was not an open-market sale or purchase but a routine mechanism tied to equity compensation.
Kiora Pharmaceuticals Chief Development Officer Eric Joseph Daniels reported a small tax-related share disposition. On March 3, 2026, he transferred 238 shares of common stock at $2.02 per share to satisfy tax withholding obligations. After this transaction, he directly held 26,137 common shares.
Kiora Pharmaceuticals President and CEO Brian M. Strem reported a tax-related stock transaction. On March 3, 2026, he disposed of 238 shares of common stock at $2.02 per share as a tax-withholding disposition, a method of paying tax obligations using shares. After this transaction, he directly owned 45,865 common shares.